The biotechnology sector has been instrumental in bringing Covid-19 under control. It was not the traditional large pharmaceutical vaccine specialists that led the way, but the innovative biotech firms such as BioNTech and Moderna. These companies have turned a much-discussed idea – vaccines based on RNA, a new approach – into a product and have manufactured millions of doses. That has led to valuations of some of the innovative small-cap companies accelerating to eye-wateringly high levels.
It is easy to get caught up in the hype of investing in stocks with rapidly rising share prices. However, we rely on fundamental analysis in making our investment decisions and look out for companies that boast a compelling roster of innovative products. We also ensure that these companies have experienced managers to help the business deliver long-term growth. We also seek out stocks that are fairly valued and we do not chase overhyped small-cap biotechs. In our opinion, these three stocks have good pipelines, strong management teams and fair valuations.
Orphan diseases: a high-growth niche
The experienced management team at Horizon Therapeutics (Nasdaq: HZNP) has turned the company into a high-growth “orphan disease” specialist. Orphan diseases affect a small number of patients, but still command good pricing power and favourable patent protections.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
One of the company’s current drugs is Tepezza, used to treat a rare condition called thyroid eye disease. The launch of this drug has been very successful, with peak sales estimated to exceed $3bn. In February 2021, in order to maintain its pipeline of new drugs, the company bought another orphan-disease company called Viela Bio.
Tackling multiple maladies
Alnylam Pharmaceuticals (Nasdaq: ALNY) has developed an RNA-platform technology that can regulate the production of various protein cells to help treat a number of different diseases. There are currently four drugs approved, which help to treat diseases caused by genetic mutations, in addition to a broad, growing, and therapeutically diversified pipeline of projects with the potential for high sales.
The company is adapting this technology to treat a range of other diseases. Some of these conditions are also caused by genetic abnormalities, while more common ailments such as hepatitis B and hypertension will also be tackled.
Shifting from HIV to cancer
Gilead Sciences (Nasdaq: GILD) is a mature biotech that built its business on HIV treatments. In 2011 it acquired Pharmasset, which had a pipeline drug to treat and cure hepatitis-C infections. The hepatitis-C franchise became hugely successful, generating peak sales of $10bn. But its growth rate dwindled soon after, as patients left treatment once they were cured.
Since then, a new management team has refocused the company on oncology by acquiring Immunomedics for $21bn. The jury is still out as to whether this acquisition will be considered a success; it depends on the data from a large breast-cancer study expected to be made public later in 2021. Gilead Sciences has not taken part in the recent market rally as it is considered defensive, so it is trading on a relatively low-price earnings (p/e) multiple.
-
Rightmove: Asking prices set to rise 2% in 2026 after post-Budget market reboundBuyers and sellers who held off in anticipation of the Budget will come back to the market and contribute to asking prices increasing next year, according to Rightmove
-
Coreweave is on borrowed timeAI infrastructure firm Coreweave is heading for trouble and is absurdly pricey, says Matthew Partridge
-
Coreweave is on borrowed time
AI infrastructure firm Coreweave is heading for trouble and is absurdly pricey, says Matthew Partridge
-
Renewable energy funds are stuck between a ROC and a hard placeRenewable energy funds were hit hard by the government’s subsidy changes, but they have only themselves to blame for their failure to build trust with investors
-
Profit from document shredding with RestoreRestore operates in a niche, but essential market. The business has exciting potential over the coming years, says Rupert Hargreaves
-
The war dividend – how to invest in defence stocks as the world arms upWestern governments are back on a war footing. Investors should be prepared, too, says Jamie Ward
-
Literacy Capital: A trust where great returns fund a good causeThere’s plenty to like about specialist private-equity trust Literacy Capital, says Max King
-
An AI bust could hit private credit – could it cause a financial crisis?Opinion Private credit is playing a key role in funding data centres. It may be the first to take the hit if the AI boom ends, says Cris Sholto Heaton
-
8 of the best ski chalets for sale nowThe best ski chalets on the market – from a traditional Alpine-style chalet in Switzerland to an award-winning Modernist building in Japan’s exclusive ski areas
-
Did COP30 achieve anything to tackle climate change?The COP30 summit was a failure. But the world is going green regardless, says Simon Wilson
